Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Overview Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development AstraZeneca Plc Infinity Pharmaceuticals Inc Novartis AG PIQUR Therapeutics AG Rhizen Pharmaceuticals SA Verastem Inc Vertex Pharmaceuticals Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles Bimiralisib - Drug Profile Product Description Mechanism Of Action R&D Progress BVD-723 - Drug Profile Product Description Mechanism Of Action R&D Progress duvelisib - Drug Profile Product Description Mechanism Of Action R&D Progress IPI-549 - Drug Profile Product Description Mechanism Of Action R&D Progress PQR-514 - Drug Profile Product Description Mechanism Of Action R&D Progress PQR-530 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Inhibit PIK3CG for Cystic Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress SF-2523 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit PI3K Gamma for Unspecified Indication - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PIK3CG for Chronic Obstructive Pulmonary Disease - Drug Profile Product Description Mechanism Of Action R&D Progress SPR-965 - Drug Profile Product Description Mechanism Of Action R&D Progress tenalisib - Drug Profile Product Description Mechanism Of Action R&D Progress Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones Featured News & Press Releases Dec 22, 2017: Rhizen Pharma Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma Dec 11, 2017: Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting Dec 10, 2017: Verastem Announces Clinical Data From the Pivotal Phase 3 Duo Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Dec 09, 2017: Rhizen Pharmaceuticals receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma Dec 05, 2017: Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017 Dec 05, 2017: Rhizen Pharmaceuticals announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting Nov 01, 2017: Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting Oct 31, 2017: Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA Oct 17, 2017: Verastem Pays Milestone Payment to Infinity Pharmaceuticals Oct 12, 2017: Infinity Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting Oct 11, 2017: Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer Sep 25, 2017: SignalRx Presents in silico Design of Dual PI3K/BRD4 Inhibitors for Combinatorial Activation of Anti-tumor Immunity in Treating Cancer Sep 06, 2017: Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Sep 06, 2017: Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by AstraZeneca Plc, H2 2017 Pipeline by Infinity Pharmaceuticals Inc, H2 2017 Pipeline by Novartis AG, H2 2017 Pipeline by PIQUR Therapeutics AG, H2 2017 Pipeline by Rhizen Pharmaceuticals SA, H2 2017 Pipeline by Verastem Inc, H2 2017 Pipeline by Vertex Pharmaceuticals Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

AstraZeneca Plc Infinity Pharmaceuticals Inc Novartis AG PIQUR Therapeutics AG Rhizen Pharmaceuticals SA Verastem Inc Vertex Pharmaceuticals Inc